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Abstract: The tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has shown
strong and explicit cancer cell-selectivity, which results in little toxicity toward normal tissues,
and has been recognized as a potential, relatively safe anticancer agent. However, several cancers
are resistant to the apoptosis induced by TRAIL. A recent study found that shikonin b
(alkannin, 5,8-dihydroxy-2-[(1S)-1-hydroxy-4-methylpent-3-en-1-yl]naphthalene-1,4-dione) might
induce apoptosis in TRAIL-resistant cholangiocarcinoma cells through reactive oxygen species
(ROS)-mediated caspases activation. However, the strong cytotoxic activity has limited its potential as
an anticancer drug. Thus, the current study intends to discover novel shikonin derivatives which can
sensitize the liver cancer cell to TRAIL-induced apoptosis while exhibiting little toxicity toward the
normal hepatic cell. The trypan blue exclusion assay, western blot assay, 4′,6-diamidino-2-phenylindole
(DAPI) staining and the terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)
assay as well as the ‘comet’ assay, were used to study the underlying mechanisms of cell death and
to search for any mechanisms of an enhancement of TRAIL-mediated apoptosis in the presence of
ASH. Herein, we demonstrated that non-cytotoxic doses of acetylshikonin (ASH), one of the shikonin
derivatives, in combination with TRAIL, could promote apoptosis in HepG2 cells. Further studies
showed that application of ASH in a non-cytotoxic dose (2.5 µM) could increase intracellular ROS
production and induce DNA damage, which might trigger a cell intrinsic apoptosis pathway in the
TRAIL-resistant HepG2 cell. Combination treatment with a non-cytotoxic dose of ASH and TRAIL
activated caspase and increased the cleavage of PARP-1 in the HepG2 cell. However, when intracellular
ROS production was suppressed by N-acetyl-l-cysteine (NAC), the synergistic effects of ASH and
TRAIL on hepatocellular carcinoma (HCC) cell apoptosis was abolished. Furthermore, NAC could
alleviate p53 and the p53 upregulated modulator of apoptosis (PUMA) expression induced by TRAIL
and ASH. Small (or short) interfering RNA (siRNA) targeting PUMA or p53 significantly reversed
ASH-mediated sensitization to TRAIL-induced apoptosis. In addition, Bax gene deficiency also
abolished ASH-induced TRAIL sensitization. An orthotopical HCC implantation mice model further
confirmed that co-treated ASH overcomes TRAIL resistance in HCC cells without exhibiting potent
toxicity in vivo. In conclusion, the above data suggested that ROS could induce DNA damage and
activating p53/PUMA/Bax signaling, and thus, this resulted in the permeabilization of mitochondrial
outer membrane and activating caspases as well as sensitizing the HCC cell to apoptosis induced by
TRAIL and ASH treatment.
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1. Introduction
Hepatocellular carcinoma (HCC) is one of the most common human malignancies worldwide,
especially in Asian courtiers. Despite the remarkable progress in HCC management, it is still one of the
most highly aggressive tumors, with dismal prognosis due to recurrence and metastasis [1,2]. In recent
decades, several candidate drugs have been promisingly developed for the patients who cannot be
cured by surgical resection. However, it is still necessary to find more potent chemotherapeutics with
less side effects and reduced drug resistance in the future medical management of HCC. On that
case, several novel molecular target agents have been developed for specifically interfering with
HCC growth and metastases while sparing normal cells, such as the tumor necrosis factor-related
apoptosis-inducing ligand (TRAIL) [3,4]. TRAIL can trigger the apoptosis cascades by activating
death receptors in the cell membrane and inducing the activation of initiator caspase in the extrinsic
apoptosis pathway [5]. Although TRAIL is a promising antitumor agent, various cancer cell lines,
including HCC cell lines, develop resistance to TRAIL-induced apoptosis [6,7]. Thus, researchers are
trying to discovery novel drugs to sensitize the HCC cell to TRAIL-induced apoptosis, while sparing
normal cells and tissues.
Shikonin is a natural active ingredient isolated form Lithospermum erythrorhizon. Previous studies
showed that shikonin and its derivatives could significantly inhibit oxidative stress and attenuated
hepatic inflammatory response, as well as protect chronic liver injury [4,5]. Chronic hepatic damage
may promote the initiation and development of liver cancer, therefore, the potential hepatoprotective
effects of shikonin and its derivatives in hepatitis indicate that these agents may also exert prevention or
therapeutic effects in HCC. In recent decades many researches have demonstrated that shikonin might
exhibit anti-cancer potential in various kinds of cancer, such as breast cancer, lung cancer, acute myeloid
leukemia and HCC [4,8,9]. Interestingly, a recent study found that shikonin (10 µM) might reduce
cells’ survival rate and promote apoptosis in cholangiocarcinoma cells, and the suppressive effects
could be enhanced by TRAIL treatment through reactive oxygen species (ROS)-mediated caspases
activation [7]. However, as a reversible inhibitor of the Uridine 5’-diphospho-glucuronosyltransferase
enzyme, shikonin has a high risk of inducing hepatic and renal toxicity [10]. Thus, the strong cytotoxic
activity and possible side effects have limited its potential as an anticancer drug [11–13]. Recently,
several shikonin derivatives with relatively few side effects and minimal toxicity have been developed
as potential chemotherapeutic agents against human cancer, such as acetylshikonin (ASH) [14]. ASH is
less cytotoxic than shikonin to normal cells, and it can be concluded that ASH may be a potentially
safer alternative to shikonin for cancer treatment [14,15]. Previous studies have shown that 10 µM
ASH could induce ROS production and enhance the phosphorylation of p38 mitogen-activated protein
kinase (MAPK) and c-Jun N-terminal kinase (JNK), which are in the major pathways of apoptotic cell
death [15]. Another study has demonstrated that 10 µM ASH could sensitize HCC cells to apoptosis
by activating p53, Bax, and Caspase3 [16]. In addition, ASH (10 µM) inhibited the growth of human
gastric carcinoma SGC-7901 cells in vitro and in vivo by inducing PUMA-dependent cell apoptosis,
which indicated that ASH might sensitize tumor cells to apoptosis [17]. Although ASH has been found
to be less toxic than shikonin, 10 µM ASH still has potential cytotoxicity towards normal cells [14]. Thus,
we intend to treat HCC with relatively low doses of ASH in combination with TRAIL for evaluating
the potential sensitizing effect of ASH to TRAIL-induced apoptosis.
Reactive oxygen species (ROS) can promote cells apoptosis via inducing DNA damage and
subsequently activating down-stream signal pathways. For instance, ROS can activate p53 and induce
apoptosis via the p53 up-regulated modulator of apoptosis (PUMA) up-regulation, as well as promoting
Bax translocation to mitochondria [2,18]. As a BH3-only pro-apoptotic Bcl-2 family protein, PUMA can
induce apoptotic cell death by translocation to mitochondria and promote various pro-apoptotic
members’ activation, such as Bax. Bax will facilitate Cytochrome C release from mitochondria and
activate Caspase. ROS production and DNA damage can directly activate p53 and promote PUMA
transcription, which finally induces cell apoptosis [19].
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Previous research has shown that ASH (10 µM) could suppress tumor development by inducing
PUMA-dependent cell apoptosis [17]. P53/PUMA/Bax activation may be involved in the cell-intrinsic
apoptosis pathway by ASH and exhibit synergistic effects with TRAIL-induced cell-extrinsic apoptosis
in HCC cells.
In an effort to identify the synergistic effect of ASH and TRAIL in HCC cell apoptosis, we examined
whether ASH (non-cytotoxic dosage) in combination with TRAIL could induce apoptotic cell death in
a HepG2 cell. Our results demonstrated that ASH (2.5 µM) could reverse the TRAIL resistance in the
HepG2 cell. ROS production, DNA double-strand breaks and p53-induced PUMA and Bax activation
may contribute to the sensitization effects of ASH on TRAIL-induced apoptosis. We considered that
both cellular intrinsic (p53/PUMA/Bax) and extrinsic (TRAIL) pathways contributed to HepG2 cells’
apoptosis via the synergistic antitumor effects of ASH and TRAIL.
2. Methods
2.1. Reagents and Cell Culture
Human hepatocellular carcinoma cells HepG2, Huh7 and normal hepatic cell LO2 were provided
by Dr. Wu in The University of Kansas. Wild-type and p53−/−Hep3B cells, wild-type and p53
upregulated modulator of apoptosis (PUMA)−/−Hep3B cells, HepG2 Bax+/− and HepG2 Bax−/− Cells
were provided by Prof. Shi in the University of Kansas. Cells were grown in Roswell Park Memorial
Institute (RPMI) 1640 supplemented with penicillin (5 units/mL), streptomycin (5 ug/mL), and 10%
heat-inactivated fetal bovine serum (FBS). Acetylshikonin was obtained from Huakang Pharmaceutical
Company (Deyang, China) and resolved in 0.1% dimethyl sulfoxide (DMSO). zlETD-fmk, zlEHD-fmk,
zDEVD-fmk and N-acetyl-l-cysteine (NAC) were purchased from Sigma-Aldrich Corp (St. Louis, MO,
USA). Recombinant human tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) was
purchased from R&D Systems (Wiesbaden, Germany) and resolved in PBS + 0.01% bovine serum
albumin (BSA).
2.2. Cell Viability
Hepatocellular carcinoma (HCC) cells were cultured in a 6-well microplate for 48 h, where each
well contain 1 × 104 cells. For the Trypan blue exclusion assay, cells were trypsinized and re-suspended
in 0.3 mL DMEM medium, 0.5 mL PBS and 0.4 mL of 0.5% Trypan blue solution. The samples were
mixed thoroughly, incubated at 23 ◦C for 20 min, and then 400 cells were counted by a light microscope
(Olympus, Tokyo, Japan) for calculating the cell survival. Each experiment was repeated three times.
2.3. Western Blotting
Cells were harvested and washed with PBS, lysed on ice for 30 min using commercial protein
extraction solution (TAKARA, Tokyo, Japan), and then centrifuged at 12,000× g for 10 min at
4 ◦C. The supernatants were collected, and the protein concentrations were measured using the
commercial protein assay kit (Bio-Rad Laboratories, Inc., Hercules, CA, USA). Proteins were separated
by sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to
Immobilon P membranes (Millipore, Billerica, MA, USA). Membranes were blocked in 4% non-fat
milk, then incubated with primary antibodies overnight at 4 ◦C. The catalog numbers and dilutions
of all primary antibodies are as follows. Antibodies for caspase-3 (ab13847), p53 (ab131442), PARP-1
(ab137653), phospho-H2A.X (ab 54722), caspase-8 (ab 25901), H2A.X (ab140498), and caspase-9 (ab2324)
were obtained from Abcam (Cambridge, MA, USA). The antibodies were used at dilutions 1:500,
1:200, 1:2000, 1:100, 1:100, 1:200 respectively. The primary antibodies for actin (61R-1159) (dilutions
1:200) was purchased from Fitzgerald Industries International, Inc. (Acton, MA, USA), Bax (2772) and
PUMA (12450) were purchased from Cell Signaling Technology (Danvers, MA, USA) that were used at
dilutions 1:1000 and 1:200. Then proteins were incubated with horseradish peroxidase-conjugated
secondary antibodies for 2 h at 23 ◦C.
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The protein bands were detected using the ECL Western Blotting Analysis System (Bio-Rad,
Philadelphia, PA, USA). Chemiluminescent signals were examined by ImageQuant LAS 4000 (Bio-Rad,
Philadelphia, PA, USA). Each experiment was repeated three times.
2.4. Apoptosis Assessment by DAPI Staining and TUNEL Assay
HCC cells were cultured on the glass slides for 12 h and treated with acetylshikonin (ASH) for
24 h at different concentrations. The HCC cells were cultured for 1, 2 and 3 days in a humidified
atmosphere of 4% CO2 at 36 ◦C. Cells were fixed in a 4% formaldehyde solution in PBS and then
permeabilized with Triton X-100 (0.1% in PBS) after incubation. Then, cells were stained with 4′,
6-diamidino-2-phenylindole (DAPI) in PBS (2.5 µg/mL) and allowed to stand for 20 min away from
light. Finally, morphological changes were analyzed by fluorescence microscopy (Olympus, Tokyo,
Japan). The apoptotic cells were also analyzed by using the In Situ Nick End-Labeling (TUNEL) assay
using the ApopTag kit (Millipore, Billerica, MA, USA) principally following the supplier’s instruction.
Images were captured using a Leica scanning confocal microscope (TCS SP5, Leica Microsystems,
Ernst-Leitz-Strasse, Wetzlar, Germany).
2.5. ROS Production Assessment
For intracellular ROS visualization and determination, cells were incubated with 20 µM
carboxy-H2DCFDA (Sigma-Aldrich, St. Louis, MO, USA) in RPMI for 40 min at 37 ◦C and washed
with PBS twice. Fluorescence was visualized by using a fluorescent microscope (Olympus, Tokyo,
Japan). The relative fluorescence intensity was detected by a microplate reader (SpectraMax; Molecular
Devices, San Jose, CA, USA) with an excitation wavelength at 480 nm and an emission wavelength at
510 nm.
2.6. DNA Comet Assay
HepG2 cells with ASH vehicle were suspended in 1.5% agarose at 35 ◦C and layered on a frosted
slide from the Trevigen Comet assay kit (Gaithersburg, MD, USA). The slides were submerged in
pre-cooled lysis buffer containing 2.5 M NaCl, 100 mM ethylenediaminetetraacetic acid (EDTA),
1.5% Triton X-100, 15 mM Tris-HCl and 9% DMSO) and stored at 4 ◦C for 12 h. After washing the
slides twice with enzyme buffer and then incubating them in enzyme buffer at 36 ◦C for 30 min,
the slides were washed with enzyme buffer and denatured in cold NaOH (300 mM) with 1 mM EDTA
in a horizontal electrophoresis chamber for 25 min. Electrophoresis voltage and currents were set
as 20 V and 300 mA for 45 min. Then, slides were incubated in cold neutralizing buffer for 20 min
and immersed in 75% ethanol for 3 min and then allowed to air dry. Finally, samples were stained
with Vista Green DNA dye at 23 ◦C for 20 min away from light. The results were visualized by
a fluorescent microscope (Olympus, Tokyo, Japan) and quantified by the Comet Assay software
(Casplab, Gaithersburg, MD, USA). Tail moment was analyzed by calculating the percentage of tail
DNA multiplied by the tail length.
2.7. siRNA Transfection
HepG2 cells were seeded at a density of 1 × 105 cells/35-mm dish or 5 × 105 cells/90-mm dish,
and then the cells were transfected by Opti-MEM, containing 5 µL/mL Lipofectamine 2000 and
50 nM p53 or PUMA small (or short) interfering RNA (siRNA) for 10 h, as previously described [20].
The sequences of the siRNA are indicated in Table 1. HepG2 cells were collected 48 h after transfection.
The efficiency of siRNA transfection was confirmed by western blot assay.
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Table 1. Sequences for small (or short) interfering RNA (siRNA) transfection.
Gene Name Gene Bank ID siRNA Sequences
P53 AB082923 F: 5
′-CUCCAUCUGGGAAUGACUU-3′
R: 5′-UAUCCAAUCUGAACUGGAC-3′
PUMA AF354654 F: 5
′-GUGCCAUUGCGAAUGAAUA-3′
R: 5′-ACUUCAUUCUCAAGUGACC-3′
2.8. Orthotopic Transplantation Tumor Model of HCC Preparation and Treatment
HepG2 cells (2 × 106) were subcutaneously injected into the flanks of 4-weeks-old male BALB/C
nude mice. Once it reached a diameter of 1 cm, the subcutaneous tumor was cut into approximately
1 mm3 pieces and implanted into the capsule of left liver lobes at an angle of 20◦. For surgical
orthotopic liver tumor implantation, nude mice were anesthetized with an intravenous injection
of 0.5% sodium pentobarbital (Nembutal, 25 mg/kg). Absorbable sutures were performed for
skin closure. All of the animal protocols were approved by the Ethics committee for animal
experiments in Kansas University (Approval number: AM (KU) 2018-0124), and the method was
carried out following the approved guideline. To relieve pain after surgery, nude mice were received
meloxicam (2 mg/kg) orally for seven days. Then the mice were randomized into two groups (n = 5).
One group received ASH (1 µg/g body weight) and TRAIL (100 ng/g body weight) every two days via
subcutaneous injection for four weeks. The control group mice received the same volume of vehicle
(PBS + 0.01% BSA + 0.1% DMSO). The dosage of ASH and TRAIL were calculated based on previous
research [7,21,22]. The tumor-bearing mice were sacrificed after four weeks treatment, and livers were
excised and photographed. The numbers of tumor nodules in the livers of mice in different groups
were analyzed by two independent researchers. The expressions of P53, PUMA and Bax in tumor
tissue were analyzed by immunohistochemical assay.
2.9. Immunohistochemistry
Liver tumor sections were embedded in paraffin before being fixed in 8% buffered formalin
solution for 12 h. Then the paraffin-embedded hepatic tumor tissues were analyzed for any expression
of Bax, PUMA and p53 by immunohistochemistry as previously described [23]. Tumor tissue sections
were incubated with primary anti-PUMA, anti-Bax from Cell Signaling Technology (Boston, MA,
USA) and anti-P53 antibodies from Abcam (Boston, MA, USA). Incubation with an appropriate
secondary antibody was followed by direct diaminobenzidine staining and light counterstaining
with hematoxylin.
2.10. Kidney and Liver Function Tests
Blood samples were collected from the control and treated mice for analysis of liver and kidney
functions at the end of the experiment following mice sacrificing. The blood urea nitrogen, serum
creatinine, alanine transaminase and aspartate transaminase levels were determined by using a fully
automated random access clinical chemistry analyzer (Beckman Synchron CX5, Foster, CA, USA).
2.11. Statistical Analyses
The data from above experiments are presented as the mean± standard error of measurement (SE).
Differences between groups were analyzed by one-way analysis of variance (ANOVA) and the Dunnett
test for multiple comparisons (SigmaPlot for Windows version 12.0; Systat Software, Inc., San Jose, CA,
USA). p values less than 0.05 were considered to represent a statistically significant difference.
Cells 2019, 8, 1466 6 of 19
3. Results
3.1. TRAIL Resistance in Human HepG2 Cell
To examine TRAIL sensitivity in HCC cells, HepG2 and Huh7 cells were exposed to TRAIL
(0–200 ng/mL) for 8 h. The cell survival result indicated that TRAIL (50–200 ng/mL) significantly
inhibited the cell viability of Huh7 cells dose-dependently (Figure 1A). The cell viability of Huh7
decreased by 34.35 ± 1.5%, 49.2 ± 2.97% and 60.32 ± 4.74% following 50, 100 and 200 ng/mL TRAIL
treatments for 8 h, respectively. But the viability of HepG2 cells was approximately 91% after exposure
to 200 ng/mL TRAIL. Furthermore, poly (ADP-ribose) polymerase-1 (PARP-1) cleavage, which is a
validated indicator of cellular apoptosis, was only observed in Huh7 cells (Figure 1B). The apoptotic
effects of TRAIL were further demonstrated by DAPI staining and the TUNEL assay.
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Figure 1. The tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) inhibits cell viability
and induces apoptosis in Huh7 cells. (A) The HepG2 and Huh7 cells’ survival rates were detected by
the Trypan blue dye exclusion assay following TRAIL treatment (0–200 ng/mL) for 8 h. Our control
group received an equal amount of vehicle (PBS + 0.01% BSA) * p < 0.05; ** p < 0.01. (B) After TRAIL
treatment (0–200 ng/mL), western blot was applied to examine PRAP-1 cleavage in HepG2 and Huh7
cells. (C) HepG2 and Huh7 cells were subjected to 4′,6-diamidino-2-phenylindole (DAPI) staining.
Apoptotic cell death as co pared bet een different cell lines after 100 ng/ L TRAIL treat ents.
Chro atin condensation of the tu or cells as sho n ith hite arro s observed by fluorescence
icroscopy. For the ter inal deoxynucleotidyl transferase d TP nick end labeling (T EL) assay,
the orphologic changes in apoptotic hepatocellular carcinoma (HC ) cells (green) were detected by a
laser scanning confocal microscope (Magnification× 200).
H pG2 and Huh7 cells were subjected to DAPI taining after 100 ng/mL TRAIL treatment.
Apoptotic cell death was compared between different cell lines. As shown in Figure 1C, in the DAPI
staining image, distinct subcellular morphological changes of apoptosis (chromosome condensation)
were observed in Huh7 cells, but not in HepG2 cells after the TRAIL treatment. For the TUNEL
assay, the morphologic changes in apoptotic Huh7 cells were detected by a laser scanning confocal
microscope after TRAIL treatment (Magnification× 200), which indicated DNA fragmentation within
the Huh7 cells, while no fluorescence signal has been detected in the HepG2 group. These results
indicated that Huh7 cells were sensitive to apoptosis-induced by TRAIL treatment, while HepG2 cells
were resistant to TRAIL, which is consistent with the previous studies [24].
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3.2. The Synergetic Effects of ASH and TRAIL on HCC Cells Apoptosis
We next determined whether applying ASH could induce cell death in a HepG2 cell. HepG2 cells
were treated with ASH (0–10 µM) for 8 h, and cell survival rates were examined by the Trypan blue
dye exclusion assay. Our data showed that 2.5 µM ASH used alone could not reduce the cell viability
of this HepG2 cell (Figure 2A). Interestingly, 2.5 µM ASH combination with a low dose of TRAIL
(50 ng/mL) could significantly suppress cells’ viability of HepG2 cells (Figure 2B). Figure 2C confirms
that no obvious cleavages of PARP-1 were detected after ASH (1–5 µM) or TRAIL (50 ng/mL) exposure,
respectively. In contrast, non-cytotoxic doses of ASH (2.5 µM) combined with 50 ng/mL TRAIL
significantly promoted the cleavage of PARP-1 in HepG2 cells. To our surprise, ASH combined with
TRAIL did not influence the cleavage of PARP-1 in a normal human hepatocyte LO2 cell (Figure 2D).
In addition, DAPI staining and TUNEL assay clearly indicated the induction of apoptotic cell death in
HepG2 cells after being co-treated with 50 ng/mL TRAIL and 2.5 µM ASH (Figure 2E).
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Figure 2. Non-apoptosis-inducing doses of acetylshikonin (ASH) reversed the resistance to
TRAIL-induced apoptosis in the HepG2 cell. (A) After ASH treatment (1–10µM) or vehicle (0.1%
dimethyl sulfoxide (DMSO)) for 8 h, cell survival rates were examined in HepG2 cells. (B) HepG2
cells were treated with ASH (0–10µM) and TRAIL (50 ng/mL), and survival rates were detected by
the Trypan blu dye exclusion assay. * p < 0.05; ** p < 0. 1 (C) Human hepatoma HepG2 ce ls and
(D) normal hepatocytes LO2 cells were exposed to TRAIL (50 ng/mL) nd 2.5 µM ASH for 12 h.
Cell lysates were prepared after treatment and analyzed by Western blotting assay using antibodies
specific to PARP-1and Actin. (E) Cell apoptosis was assessed by our TUNEL assay and DAPI staining
(Magnification× 200).
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3.3. Combination Therapy with TRAIL and ASH Activates Caspases Signaling Pathway
Next, the underlying mechanisms as to how TRAIL-mediated apoptosis was enhanced in HepG2
cells by ASH were investigated. We examined the cleavage of PARP-1, caspase-9, caspase-3 and
caspase-8 in HepG2 cells to explore the regulation of the apoptotic signaling pathway after TRAIL
and ASH treatment. No obvious cleavage of Caspase-3/-8/-9 or PARP-1 were detected following
treatment with 2.5 µM ASH or 50 ng/mL TRAIL, respectively in this HepG2 cell (Figure 3A). In contrast,
TRAIL (50 ng/mL) and ASH (2.5 µM) combination therapy lead to significant caspases and PARP-1
cleavages time-dependently (Figure 3A). In addition, the cleavages of caspases were increased by
ASH dose-dependently (Figure 3B). Several caspases inhibitors such as zlETD-fmk, zlEHD-fmk and
zDEVD-fmk were applied to validate the potential role of caspases cleavages in HepG2 cell survival
after combination treatment.
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applied to HepG2 cells to block the caspase pathway. Then the cells were exposed to 2.5 μM ASH 
and/or TRAIL 50 ng/mL for 12 hours. Cells’ survivals were assessed via the Trypan blue dye 
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3.4. ASH Promotes ROS Production in HepG2 Cells 
It is widely accepted that the reactive oxygen species (ROS) plays a pivotal role in cell 
apoptosis. Thus, we assessed the effects of ASH and TRAIL on the intracellular redox status of 
HepG2 cells after 48 h treatment. Firstly, we detected the cellular ROS production after ASH 
treatment via applying the CARBOXY-H2DCFDA fluorescence probes. Figure 4A indicates that 
HepG2 cells pretreated with H2O2 (positive control) or ASH (1, 2.5 μM) exhibited an obvious 
fluorescence signal compared to control groups observed under a fluorescence microscope. The 
Figure 3. Combination therapy with ASH and TRAIL results in the activation of caspase in the HepG2
cell. (A) The cleavage of caspases and PARP-1 in HepG2 cells were analyzed via Western blotting after
following 4–24 h treatment with 2.5 µM ASH and/or 50 ng/mL TRAIL, and the control group received
an equal amount of vehicle (PBS + 0.01% BSA + 0.1% DMSO). (B) Western blotting was applied to
determine the cleavage of caspase family members in HepG2 cells after treatment with 0.5–2.5 µM of
ASH and 50 ng/mL TRAIL for 12 h. (C) The specific c spas s inhibitors were applied to HepG2 cells to
block the caspase pathway. Then the cell w re exposed to 2.5 µM ASH and/or TRAIL 50 ng/mL for
12 h. Cells’ survivals were assessed via the Trypan blue dye exclusion assay and Western blotting was
applied to determine the cleavage of PARP-1. ** p < 0.01.
Our data demonstrated that both the cleavage of PARP-1 and apoptosis in HepG2 cel s were
reversed by caspases inhibition (Figure 3C). In general, activation of caspases signaling might have
contributed to apoptosis in the HepG2 cell mediated by non-cytotoxic doses of TRAIL and ASH.
3.4. ASH Promotes ROS Production in HepG2 Cells
It is widely accepted that the reactive oxygen species (ROS) plays a pivotal role in cell apoptosis.
Thus, we assessed the effects of ASH and TRAIL on the intracellular redox status of HepG2 cells after
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48 h treatment. Firstly, we detected the cellular ROS production after ASH treatment via applying the
CARBOXY-H2DCFDA fluorescence probes. Figure 4A indicates that HepG2 cells pretreated with H2O2
(positive control) or ASH (1, 2.5 µM) exhibited an obvious fluorescence signal compared to control
groups observed under a fluorescence microscope. The relative fluorescence intensity was enhanced
by ASH according to the results from the fluorescence plate reader, which indicated that ASH may
promote ROS production dose-dependently (Figure 4B). The maximum value of relative fluorescence
intensity was presented at 20 min after ASH (2.5, 5 µM) treatment. Then, the relative fluorescence
intensity quickly decreased and achieved a minimal value after ASH treatment 60 min later. However,
the fluorescence intensity climbed again after ASH treatment for four hours (Figure 4C). The above
data indicated that ASH increased the cellular ROS level in a biphasic pattern in the HepG2 cell.Cells 2019, 8, x FOR PEER REVIEW 10 of 19 
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for 60 min and labeled with CMH2DCFDA (20 µM/L) for 20 min. The positive control group or ASH
(2.5, 5 µM) group showed significant higher fluorescence intensity as compared to the vehicle (PBS +
0.01% BSA) control group. (B) After exposure with ASH (2.5, 5 µM) for various times, the intracellular
ROS production in HepG2 cells was analyzed by the relative fluorescence intensity. * p < 0.05; ** p < 0.01;
*** p < 0.001 (C) HepG2 cells were labeled with CMH2DCFDA after treating with ASH (2.5, 5 µM) for
different times. ROS productions at different time-points were quantified by the relative fluorescence
intensity using the fluorescence plate reader. * p < 0.05 (D) Pretreated with N-acetyl-l-cysteine (NAC)
(ROS inhibitor) significantly decreased the ROS level induced by ASH (25 µM), and (E) reversed ASH-
and TRAIL-mediated HepG2 cell death. * obvious changes between ASH and TRAIL + ASH group
(p < 0.05). ** Obvious changes between NAC+ TRAIL + ASH group and TRAIL + ASH group (p < 0.01).
Control group received an equal amount of vehicle (PBS + 0.01% BSA + 0.1% DMSO). (F) Western
blotting was applied to determine the cleavage of PARP-1 and the expression of p53, and the p53
upregulated modulator of apoptosis (PUMA) after pretreatment of NAC in combination with ASH
and/or TRAIL.
To explore the potential role of ROS in ASH- and TRAIL-induced HepG2 cell apoptosis, cells were
exposed to NAC (ROS inhibitor), and then these cells were treated with TRAIL (50 ng/mL) and ASH
(2.5 µM). Figure 4D shows that 50 ng/mL TRAIL did not have any effect on ROS production based on
the changes of fluorescence intensity. In addition, 4 mM NAC might decrease the ROS level induced
by 2.5 µM ASH (Figure 4D), and reverse cell death caused by ASH and TRAIL combination treatment
in a human HepG2 cell (Figure 4E). ROS can modify the cysteine residues of p53, a tumor suppressor,
leading to conformational changes that affect its transcriptional activity [25]. ASH-induced apoptotic
cell death has been associated with the up-regulating of p53 and PUMA expression in an HCC cell [16].
Thus, to reveal the mechanisms of ROS-mediated apoptosis by combination treatment with ASH and
TRAIL, the Western blotting assay was applied to examine the cleavage of PARP-1 and the expression
of p53 and PUMA in HepG2 cells. As shown in Figure 4F, TRAIL (50 ng/mL) and ASH (2.5 µM)
synergistically increased the cleavage of PARP-1 and up-regulated the expression of p53 and PUMA
in the HepG2 cell. However, 4 mM NAC alleviated the effects of ASH + TRAIL on the cleavage of
PARP-1 and reversed the increasing of p53 and PUMA expression. In conclusion, ASH and TRAIL
combination treatment may trigger the ROS-mediated intrinsic apoptosis pathway via increasing the
expression of p53 and PUMA in the HepG2 cell.
3.5. ASH Caused DNA Damage in HepG2 Cells
ROS may lead to mutations of genes and chromosomes by DNA double strand breaks in the
cell, which may further induce cell apoptotic death. To evaluate the DNA damage induced by ASH
treatment, a comet assay (single-cell gel electrophoresis) was applied to measure DNA strand breaks in
HepG2 cells. Figure 5A shows significant difference in tail length (length of DNA migration) after
2.5 µM ASH exposure 20 min later, which suggested that ASH could induce DNA damage in HepG2
cells. Above results indicated that ASH could induce DNA double strand breaks in HepG2 cells and
trigger subsequent apoptotic cell death. When a double-strand break occurs in DNA, a sequence of
events occurs in which the H2A histone family member X (H2AX) becomes phosphorylated on serine
139 [23,26]. Thus, we detected the expression of phospho-H2A.X-Ser139 and H2A.X to further confirm
ASH induced DNA damage. Figure 5B,C showed that ASH time- and dose-dependently facilitated
H2A.X phosphorylation on Ser-139 in HepG2 cell. In addition, the expression of TRAIL receptors
(DR-4 and DR-5) in TRAIL-resistant HepG2 cells were unaltered after treatment with 2.5–10 µM ASH
(Figure 5D). These results indicated that ASH might promote ROS production and DNA double-strand
breaks, as well as the H2A.X phosphorylation on Ser-139, which might further activate P53 and trigger
apoptosis in cancer.
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used to measure the double strand breaks by calculating the percentage of tail x tail length.
* p 0.05; ** p < 0.01. (B) HepG2 cells were pretreated with 1–10 µM ASH for 12 h, the expression of
phospho-H2A.X-Ser139 and H2A.X were analyzed by Western blot assay. Control group received an
equal amount of vehicle (0.01% DMSO). (C) HepG2 cells were pretreated with 2.5 µM ASH for 0, 1, 2, 4,
8, 16, and 24 h. The expressions of phosph -H2A.X-Ser139 and H2A.X were analyzed by Western blot
assay. (D) HepG2 cells were pre-incubat d with ASH at various dosages f r 12 h. The expression of
DR-4 and DR-5 was evaluated by Western blotting assay.
3.6. Involvement of p53 and PUMA in ASH-Induced TRAIL Sensitization
It has been recognized that p53 phosphorylation could affect the stabilization of itself [27].
Interestingly, our results showed that 2.5 µM ASH can induce p53phosphorylation at Ser15, Ser392 and
Ser46 residues, which facilitated the stabilization and accumulation of p53 in HepG2 cells (Figure 6A).
The P53 up-regulated modulator of apoptosis (PUMA) is a downstream target of p53. Previously,
study has shown that p53 activation can up-regulate PUMA and induce cell apoptosis after ASH
treatment [16]. Herein, we further explored the potential role of PUMA and p53 in ASH- and
TRAIL-mediated apoptotic cell death.
Figure 6B further confirms that ASH significantly increased the expressions of p53 and PUMA in
a dose-dependent manner. A significant increase of PUMA and p53 expression is observed by the
synergistic therapy of TRAIL (50 ng/mL) and a non-cytotoxic dose of ASH (Figure 6C). For further
confirming the critical role of p53 and PUMA in ASH-induced TRAIL sensitization, RNA interference
(RNAi) was applied to knock down the expression of p53 and PUMA. Figure 6D shows that at the 48-h
time point after PUMA or p53 siRNA transfection, ASH-mediated TRAIL sensitization was reversed in
PUMA- or p53 siRNA-transfected cells, as indicated by the alleviated PARP-1 cleavage. The DAPI
staining results were consistent with the Western blotting experiments (Figure 6E). In general, the above
results demonstrated that p53 and PUMA might play critical role in ASH-induced TRAIL sensitization
and apoptosis. To further confirm the involvement of p53 in TRAIL- and ASH-induced apoptosis of
different HCC cell lines, Hep3B, another TRAIL-resistant HCC cells, were performed in our study.
Two Hep3B HCC cell lines, including p53+/+ and p53−/−, were exposed to TRAIL and ASH treatment.
Our results indicated that ASH can synergize with TRAIL and induce cytotoxicity as well as up-regulate
PARP-1 cleavage in Hep3B p53+/+ cells instead of Hep3B p53−/− cells (Figure 7A,B). In another
experiment, two Hep3B cell lines (Hep3B PUMA+/+) and (Hep3B PUMA−/−) were applied to further
evaluate the potential role of PUMA in ASH- and TRAIL-induced HCC apoptosis. Figure 7C,D
demonstrate that ASH may sensitize TRAIL-induced apoptotic cell death and promote the cleavage
of PARP-1 in the Hep3B PUMA+/+ cell instead of the Hep3B PUMA−/− cell. In summary, these
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results revealed that increased expression of PUMA or p53 contributed to sensitize HCC cells to
TRAIL-induced apoptosis by ASH.
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Figure 6. ASH promotes phosphorylation and accumulation of p53 and increases PUMA expression.
(A) HepG2 cells were exposed to 2.5 µM ASH for 1, 2, 4, 8, 16 and 24 h, phosphorylation of p53 at
Ser46, Ser392 and Ser15 residues were analyzed by Western blotting assay). Control group received an
equal amount of vehicle (0.1% DMSO). (B) HepG2 cells were exposed to 1, 2.5, 5, 10 µM ASH for 12 h,
the expression of PUMA and p53 protein were analyzed by western blotting assay. (C) HepG2 cells
were exposed to 1, 2.5, 5 µM ASH with or without 50 ng/mL TRAIL for 12 h, PUMA and p53 protein
expression were analyzed by western blotting assay. (D) Small interfering RNA (siRNA) has been used
to specifically silence PUMA or p53; 48 h after transfection, the HepG2 cells were exposed to 5 µM
ASH with or without 50 ng/mL TRAIL for 12 h. The cleavage of PARP-1 and the expression of p53
and PUMA were analyzed via Western blotting assay. (E) DAPI staining test was performed to assess
the apoptosis-inducing effects of ASH and TRAIL combination therapy in HepG2 cells after P53 or
PUMA siRNA transfection. Chromatin condensation of the tumor cells was shown with white arrows
observed by fluorescence microscopy (Magnification× 200).
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3.7. Bax Contributed to ASH and TRAIL Induced Apoptosis 
After PUMA activation, it will further interact with anti-apoptotic Bcl-2 family members, thus 
freeing Bax which is then able to signal apoptotic cell death to the mitochondria [19]. To verify 
whether Bax contributed to ASH- and TRAIL-induced apoptosis, HepG2 Bax+/− and HepG2 Bax−/− 
cells were used in our study. As shown in Figures 8 A and B, TRAIL-induced cytotoxicity and 
PARP-1 cleavage were facilitated by 2.5 μM ASH synergistic treatment in the HepG2 Bax+/− cell, but 
not in the HepG2 Bax−/− cell. Interestingly, the synergistic treatment remarkably increased the 
upstream activators of Bax, such as p53 and PUMA in both cell lines (Figure 8B). In addition, the 
DAPI staining assay also clearly indicated the induction of apoptotic cell death in HepG2 Bax+/− 
cells after combination treatment with TRAIL (50 ng/mL) and 2.5 μM ASH (Figure 8C). 
Figure 7. ASH reverses TRAIL resistance and induces apoptosis in Hep3B cells by targeting p53 and
PUMA. (A,B) Wild-type and p53−/−Hep3B cells or (C,D) wild type and PUMA−/−Hep3B cells were
pretreated with ASH (2.5 µM) and TRAIL (50 ng/mL) for 12 h. Control group received an equal amount
of vehicle (PBS + 0.01% BSA + 0.1% DMSO). Cell survivals were detected by the Trypan blue dye
exclusion assay. The cleavage of PARP-1 and the expression of p53 or PUMA were analyzed via Western
blotting. * p < 0.05.
3.7. Bax Contributed to ASH and TRAIL Induced Apoptosis
After PUMA activation, it will further interact with anti-apoptotic Bcl-2 family members,
thus freeing Bax which is then able to signal apoptotic cell death to the mitochondria [19]. To verify
whether Bax contributed to ASH- and TRAIL-induced apoptosis, HepG2 Bax+/− and HepG2 Bax−/−
cells were used in our study. As shown in Figure 8A,B, TRAIL-induced cytotoxicity and PARP-1
cleavage were facilitated by 2.5 µM ASH synergistic treatment in the HepG2 Bax+/− cell, but not in
the HepG2 Bax−/− cell. Interestingly, the synergistic treatment remarkably increased the upstream
activators of Bax, such as p53 and PUMA in both cell lines (Figure 8B). In addition, the DAPI
staining assay also clearly indicated the induction of apoptotic cell death in HepG2 Bax+/− cells after
combination treatment with TRAIL (50 ng/mL) and 2.5 µM ASH (Figure 8C).
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Figure 8. Bax contributed to apoptosis induced by ASH and TRAIL. (A,B) 2.5 µM ASH and 50 ng/mL
TRAIL were exposed to HepG2 Bax+/− and HepG2 Bax−/− for 8 h. Control group received an equal
amount of vehicle (PBS + 0.01% BSA+0.1% DMSO). Cells’ survivals were detected by the Trypan
blue dye exclusion assay. The cleavage of PARP-1 and the expression of PUMA, p53 and Bax were
analyzed by the Western blotting assay * p < 0.05. (C) The DAPI staining test was performed to assess
apoptosis-inducing effects of ASH and TRAIL combination therapy in HepG2 Bax+/− and HepG2
Bax−/− cells. Chromatin condensation of the tumor cells was shown with white arrows observed by
fluorescence microscopy (Magnification× 200).
3.8. I I i its umor Growth in Orthotopically Transplanted Mouse HC
e next sought to determine whet er ASH and TRAIL combination treatment can inhibit tumor
growth in ort otopically transplanted mouse HCC. Tumor-bearing mice treat d with ASH (1 µg/g
body weight) + TRAIL (100 ng/g body weight) every two days via ubcutaneous injection for four
weeks, showed 2.7-fold reduction in the tumor nod les number in livers compared to our control group
(p < 0.05 Fig re 9A). For detecting the potential side effect of ASH + TRAIL, we examined the body
weight of mic during the treatment. As shown in Figur 9B, there were o obvious chang s in body
weight between the two groups (p < 0.05). W further detected the effects of ASH + TRAIL on kidney
and liver functi s. We did not find significant differences o blood urea nitrogen, serum creatinine,
alanin transa inase and asp rtate tra sa inase level between the two groups (p < 0.05) (Table 2).
Together, these results suggest that ASH + TRAIL has no significant side effects in mice. In addition,
the IHC results showe that the number of positive cells and the intensity of staining for p53, Bax and
PUMA were sig ificant higher in liver cancer tissu in the ASH + TRAIL group compared with vehicle
treated controls. (p < 0.05 Figure 9C).
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weight) + TRAIL (100 ng/g body weight) might not have significant cytotoxicity in vivo. (C) P53, 
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Figure 9. ASH and TRAIL combination treatment inhibits tumor growth in orthotopically transplanted
mouse HCC (A) The amount of tumor nodules in livers from tumor-bearing mice after ASH (1 µg/g body
weight) and TRAIL (100 ng/g body weight) combination treatment via subcutaneous injection for four
weeks. Mice in the control group received an equal amount of vehicle (PBS + 0.01% BSA + 0.1% DMSO)
(** p < 0.01). (B) Body weight of tumor-bearing mice was examined during treatment. No obvious loss in
body weight could be detected, suggesting ASH (1 µg/g body weight) + TRAIL (100 ng/g body weight)
might not have significant cytotoxicity in vivo. (C) P53, PUMA and Bax expression were assessed by
immunostaining; the final immunostaining score was calculated by multiplying the intensity score with
the percentages of positive cell observed by electron microscopy at 200×magnification. The intensity
of staining was scored by three independent researchers as 0 = no staining, 1 = weak staining and
2 = significant staining. Cancer cells in four fields were selected randomly and scored based on the
percentage of positive staining cell (** p < 0.01).
Table 2. The effects of ASH+TRAIL on kidney and liver functions in mice.
Serum Chemistry Control ASH + TRAIL p-Value
Blood urea nitrogen (mg/dL) 54.7 ± 4.97 49.8 ± 2.57 0.221
Serum creatinine (µmol/L) 105.48 ± 8.52 112.60 ± 7.58 0.647
Alanine transaminase (U/L) 59.78 ± 9.39 67.48 ± 12.81 0.569
Aspartate transaminase (U/L) 323.94 ± 71.4 380.15 ± 87.3 0.309
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4. Discussion
Apoptosis can be triggered by extracellular stimuli (extrinsic pathway) or irritation within the
cells (intrinsic pathways). For intrinsic apoptosis, the cell death was induced by cell stress such as
DNA damage and subsequently p53 activation. For extrinsic apoptosis the cell kills itself due to signals
from other cells mediated by binding to death ligands and their receptors. Caspases orchestrate both
extrinsic and intrinsic apoptosis by activating target protein cleavage [28]. TRAIL, also recognized as
Apo2L, belongs to the TNF superfamily, which could induce cell apoptosis via activating the extrinsic
apoptosis pathway. The pre-treatment of the cancer cell by small molecules inhibitor has been shown
to improve the sensitivity of TRAIL-induced apoptosis while sparing the normal cell [29]. These novel
agents include the mammalian target of the rapamycin (mTOR) inhibitor [30], BCL-2 inhibitor [31],
histone deacetylases (HDAC) inhibitor [32] and proteasome inhibitor [33], which have been used for
combination with TRAIL to suppress the specific signal molecule that might synergistically promote
a TRAIL-induced extrinsic apoptosis pathway. In this study, we found that non-cytotoxic dosage of
ASH might sensitize HepG2 cells to TRAIL-induced apoptosis via up-regulating the expression of p53,
PUMA and Bax through oxidative DNA damage induced by ROS. Mitochondria-mediated activation
of caspase-9 was involved in the intrinsic apoptosis signal pathway induced by ASH via the promotion
of ROS production, while death-receptor mediated activation of caspase-8 might contribute to the
extrinsic apoptosis signal pathway by TRAIL (Figure 10).
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Figure 10. Diagram of molecular mechanisms underlying the synergic effects between ASH and TRAIL
in promoting apoptotic cell death in HCC.
TRAIL therapy has been introduced for cancer treat ent by inducing an extrinsic apoptosis
pathway for more than twenty years. However, various tumor cells showed resistance to TRAIL
treatment [6]. Herein, our data showed that the liver cancer cells Huh7 were sensitive to TRAIL-induced
apoptosis, while HepG2 cells were resistant. Above results were consistent with previous research on
TRAIL-sensitive or -resistant HCC cells [31].
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More importantly, our data indicated that non-toxic dosage of ASH in combination with TRAIL
significantly induced apoptotic cell death in the HepG2 cell. These findings suggested that ASH
might have synergistic or sensitizing effects on TRAIL-mediated apoptosis. In the intrinsic pathway of
apoptosis, opening the permeability transition pore complex on the mitochondrial membrane plays a
critical role in the subsequent release of cytochrome C, formation of apoptosome and in activating
caspase. Caspases are a family of cysteine aspartyl proteases which constitutes the effector arm of
the apoptotic machinery. When caspases are activated, they will trigger the cleavage of various
intracellular proteins to bring programed cell death by apoptosis [34]. Our data suggested that ASH
and TRAIL synergistically up-regulated caspase-3, -8 and -9 expressions, which confirmed the pivotal
role of caspases in the apoptosis of HCC cells. ROS can open the pore via pore-destabilizing proteins’
activation such as Bax [11]. In our study, an increased intracellular ROS level was observed after
ASH exposure. In addition, ASH significantly induced DNA double strand breaks in our HepG2 cell.
Combination therapy with non-toxic doses of TRAIL and ASH resulted in the activation of caspase and
the cleavage of PARP-1 in HepG2 cells, which may contribute to the ROS-induced intrinsic pathway
of apoptosis. Interestingly, the application of an antioxidant such as NAC obviously suppressed the
intracellular ROS level and the cleavage of PARP-1, thus alleviating the cancer cells’ apoptosis induced
by the synergistic treatment with ASH and TRAIL. Furthermore, NAC also blocked the expression of
p53 and PUMA in the HepG2 cell, which would inhibit cell apoptosis. PUMA is an important mediator
of p53-dependent apoptosis, which can transduce death signals to the mitochondria, where it indirectly
activates Bax and subsequently induces mitochondrial dysfunction and caspase activation [28,35].
Here we showed an increased expression of Bax and PUMA in HCC cells following exposure to ASH
and TRAIL. P53 and PUMA silencing or Bax gene deficiency could reverse ASH-induced TRAIL
sensitization in HCC. Above data suggested that ROS played a critical role in DNA damage and
activating p53/PUMA/Bax signaling, thus leading to the permeabilization of the mitochondrial outer
membrane and the activation of caspases as well as sensitization of HCC cells to TRAIL-induced
apoptosis by ASH. Although several natural compounds or small molecules have been reported to
induce cell death by promoting ROS production, their mechanisms as to how ROS is induced are
still largely unclear. Therefore, the mechanisms underlying the pharmacological activity of ASH in
increasing the intracellular ROS level will be further studied in our future research.
Next were further examined the protective effects of ASH and TRAIL in the orthotopically
HCC-implanted mice. The in vivo results indicated that the combination therapy may inhibit HCC
development without significant cytotoxicity to mice. The immunohistochemistry (IHC) analysis for
p53, PUMA and Bax expression from tumor tissue also confirmed our in vitro results. In summary,
we demonstrated that HCC cells co-treated with ASH and TRAIL will result in ROS production,
DNA double strand breaks and p53-mediated PUMA and Bax up-regulation, followed by caspases
activation and consequently inducing apoptosis in the HepG2 cell while sparing the normal hepatic
LO2 cell. Despite our encouraging findings in this study, several questions remain, such as how ROS
is induced by ASH, and the safety and efficacy of our combination treatment of ASH and TRAIL on
cancer patients. In addition, whether this combination has a “synergistic” effect on the inhibition of
HCC cells’ survival should be further studied by in silico-based automated simulation of synergism,
at all dose or effect levels, as previously described [36]. These questions need to be carefully answered
by our future studies.
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